Accelerated and blastic phases of chronic myelogenous leukemia

Hematology/Oncology Clinics of North America

Volumn 18, Issue 3, 2004, Pages 753-774

  Giles, Francis J ^a   Cortes, Jorge E ^a   Kantarjian, Hagop M ^a   O'Brien, Susan M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 5 AZA 2' DEOXYCYTIDINE; AP 23573; ARSENIC TRIOXIDE; ARYLBUTYRIC ACID DERIVATIVE; BEVACIZUMAB; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; IDARUBICIN; IMATINIB; LBH 589; LONAFARNIB; MITOXANTRONE; NUCLEOSIDE ANALOG; PEGINTERFERON; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAPAMYCIN DERIVATIVE; RECOMBINANT ALPHA INTERFERON; RETINOID DERIVATIVE; SEMAXANIB; TEMSIROLIMUS; TIPIFARNIB; TROXACITABINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VATALANIB; VINCRISTINE;

BASOPHIL; BLAST CELL CRISIS; BONE MARROW SUPPRESSION; CANCER RISK; CANCER SURVIVAL; CELL CYCLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DIAGNOSTIC PROCEDURE; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; HAND FOOT SYNDROME; HIGH RISK POPULATION; HUMAN; LABORATORY TEST; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SOUTHERN BLOTTING; STOMATITIS; THROMBOCYTE COUNT; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BLAST CRISIS; CLONE CELLS; HUMANS; LEUKEMIA, MYELOID, AGGRESSIVE-PHASE; LEUKEMIA, MYELOID, CHRONIC; TREATMENT OUTCOME;

EID: 3242748217     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2004.03.005     Document Type: Review

References (177)

1. Faderl S., Talpaz M., Estrov Z., et al. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 131(3):1999;207-219
2. Faderl S., Talpaz M., Estrov Z., et al. The biology of chronic myeloid leukemia. N Engl J Med. 341(3):1999;164-172
3. Speck B., Bortin M.M., Champlin R., et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet. 1(8378):1984;665-668
4. Clift R.A., Buckner C.D., Thomas E.D., et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood. 84(12):1994;4368-4373
5. Kantarjian H.M., Dixon D., Keating M.J., et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 61(7):1988;1441-1446
6. Savage D.G., Szydlo R.M., Chase A., et al. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol. 99(1):1997;30-35
7. Sokal J.E., Gomez G.A., Baccarani M., et al. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood. 72(1):1988;294-298
8. Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma. 11(Suppl 1):1993;11-15
9. Majlis A., Smith T.L., Talpaz M., et al. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol. 14(1):1996;196-203
10. Cortes J., Talpaz M., O'Brien S., et al. Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. J Clin Oncol. 16(10):1998;3279-3285
11. Talpaz M., Silver R.T., Druker B.J., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 99(6):2002;1928-1937
12. Kantarjian H.M., Talpaz M., Kontoyiannis D., et al. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 10(3):1992;398-405
13. Kantarjian H.M., O'Brien S., Smith T.L., et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol. 17(1):1999;284-292
14. Kantarjian H.M., Giles F.J., O'Brien S, et al. Therapeutic choices in younger patients with chronic myelogenous leukemia. Cancer. 89(8):2000;1647-1658
15. Kantarjian H.M., Smith T.L., O'Brien S., et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med. 122(4):1995;254-261
16. Kantarjian H.M., Keating M.J., Estey E.H., et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol. 10(5):1992;772-778
17. Karnam U.S., Reddy K.R. Pegylated interferons. Clin Liver Dis. 7(1):2003;139-148
18. Choueiri T.K., Hutson T.E., Bukowski R.M. Evolving role of pegylated interferons in metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 3(6):2003;823-829
19. Michallet M., Maloisel F., Delain M., et al. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia. 18(2):2004;309-315
20. Rosti G., Trabacchi E., Bassi S., et al. Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica. 88(3):2003;256-259
21. Bukowski R.M., Tendler C., Cutler D., et al. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer. 95(2):2002;389-396
22. Pehamberger H. Perspectives of pegylated interferon use in dermatological oncology. Recent Results Cancer Res. 160:2002;158-164
23. Druker B.J., Sawyers C.L., Capdeville R., et al. Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program). 2001;87-112
24. Talpaz M. Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition. Semin Hematol. 38(3 Suppl 8):2001;22-27
25. Wang Y.S., Youngster S., Bausch J., et al. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry. 39(35):2000;10634-10640
26. Heathcote E.J., Shiffman M.L., Cooksley W.G., et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 343(23):2000;1673-1680
27. Zeuzem S., Feinman S.V., Rasenack J., et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 343(23):2000;1666-1672
28. Talpaz M., O'Brien S., Rose E., et al. Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 98(6):2001;1708-1713
29. Kantarjian H., O'Brien S., Cortes J., et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 8(7):2002;2167-2176
30. Kantarjian H.M., Cortes J., O'Brien S., et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 99(10):2002;3547-3553
31. Thomas D., Cortes J., Giles F.J., et al. Combination of Hyper-CVAD with imatinib mesylate for Philadelphia-positive adult acute lymphoblastic leukemia or chronic myelogenous leukemia in lymphoid blast phase. Blood. 98(11):2001;803a. Abstract 3340
32. El-Zimaity M.M., Kantarjian H., Talpaz M., et al. Results of imatinib mesylate therapy in chronic myelogenous leukemia with variant Philadelphia chromosome. Br J Haematol. 125(2):2004;187-195
33. Ravandi F., Kantarjian H., Giles F., et al. New agents in acute myeloid leukemia and other myeloid disorders. Cancer. 100(3):2004;441-454
34. Donato N.J., Wu J.Y., Stapley J., et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 64(2):2004;672-677
35. Esmaeli B., Diba R., Ahmadi M.A., et al. Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec). Eye. 2004;. in press
36. Kantarjian H., O'Brien S., Cortes J., et al. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res. 10(1):2004;68-75
37. Kantarjian H., Talpaz M., O'Brien S., et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 103(8):2004;2873-2878
38. Sneed T.B., Kantarjian H.M., Talpaz M., et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. 100(1):2004;116-121
39. Kantarjian H.M., O'Brien S., Cortes J., et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer. 98(12):2003;2636-2642
40. Tsao A.S., Kantarjian H., Cortes J., et al. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 98(11):2003;2483-2487
41. Medina J., Kantarjian H., Talpaz M., et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer. 98(9):2003;1905-1911
42. Thomas D.A., Faderl S., Cortes J., et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood, in press
43. Kantarjian H., O'Brien S., Cortes J., et al. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Cancer. 98(7):2003;1430-1437
44. Cortes J., Talpaz M., O'Brien S., et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 98(6):2003;1105-1113
45. O'Brien S., Giles F., Talpaz M., et al. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer. 98(5):2003;888-893
46. Gatto S., Scappini B., Pham L., et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica. 88(8):2003;853-863
47. Giles F.J., Feldman E.J., Roboz G.J., et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk Res. 27(12):2003;1091-1096
48. Kantarjian H.M., O'Brien S., Cortes J., et al. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 98(3):2003;522-528
49. Kantarjian H., O'Brien S., Cortes J., et al. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer. 98(1):2003;81-85
50. Tsimberidou A.M., Colburn D.E., Welch M.A., et al. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol. 52(3):2003;229-234
51. Cortes J., Giles F., O'Brien S., et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer. 97(11):2003;2760-2766
52. Kurzrock R., Kantarjian H.M., Druker B.J., et al. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med. 138(10):2003;819-830
53. Kantarjian H., Talpaz M., O'Brien S., et al. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 97(9):2003;2225-2228
54. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 348(13):2003;1201-1214
55. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 348(11):2003;994-1004
56. Cortes J., Giles F., O'Brien S., et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood. 102(1):2003;83-86
57. Mattiuzzi G.N., Cortes J.E., Talpaz M., et al. Development of varicella-zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res. 9(3):2003;976-980
58. Cortes J., Ault P., Koller C., et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 101(12):2003;4714-4716
59. Kantarjian H.M., O'Brien S., Cortes J.E., et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 97(4):2003;1033-1041
60. Cortes J., Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin Hematol. 40(1):2003;79-86
61. Cortes J.E., Talpaz M., Giles F., et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 101(10):2003;3794-3800
62. Kantarjian H.M., Talpaz M., Cortes J., et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 9(1):2003;160-166
63. Kantarjian H.M., Cortes J.E., O'Brien S., et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 101(1):2003;97-100
64. Kantarjian H.M., Talpaz M., O'Brien S., et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 101(2):2003;473-475
65. Esmaeli B., Prieto V.G., Butler C.E., et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer. 95(4):2002;881-887
66. Kantarjian H.M., O'Brien S., Cortes J.E., et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 100(5):2002;1590-1595
67. Scappini B., Onida F., Kantarjian H.M., et al. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer. 94(10):2002;2653-2662
68. Ault P., Cortes J., Koller C., et al. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 26(9):2002;881-884
69. Atallah E., Talpaz M., O'Brien S., et al. Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. Cancer. 94(11):2002;2996-2999
70. Kantarjian H.M., Talpaz M., O'Brien S., et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res. 8(7):2002;2177-2187
71. Kantarjian H.M., O'Brien S., Cortes J.E., et al. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 8(7):2002;2167-2176
72. Garcia-Manero G., Talpaz M., Kantarjian H.M. Current therapy of chronic myelogenous leukemia. Intern Med. 41(4):2002;254-264
73. O'Brien S., Talpaz M., Cortes J., et al. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer. 94(7):2002;2024-2032
74. Talpaz M., Silver R.T., Druker B.J., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 99(6):2002;1928-1937
75. Kantarjian H., Sawyers C., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 346(9):2002;645-652
76. Kantarjian H.M., Talpaz M. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Semin Oncol. 28(5 Suppl 17):2001;9-18
77. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 2(5):1996;561-566
78. Druker B.J., Talpaz M., Resta D., et al. Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia. Blood. 94(Suppl 1):1999;368a
79. Druker B.J., Sawyers C.L., Kantarjian H., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 344(14):2001;1038-1042
80. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344(14):2001;1031-1037
81. Anonymous Harringtonine in acute leukemias. Clinical analysis of 31 cases. Chinese Med J. 3(5):1977;319-324
82. Anonymous The antitumor effects and pharmacologic actions of harringtonine. Chinese Med J. 3(2):1977;131-136
83. Feldman E.J., Seiter K.P., Ahmed T., et al. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia. 10(1):1996;40-42
84. Ye J.S., Wang X.H., Feng G.H., et al. Small-dose Harringtonine induces complete remission in patients with acute promyelocytic leukemia. Leukemia. 2(7):1988;427-429
85. Kantarjian H.M., Talpaz M., Smith T.L., et al. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol. 18(20):2000;3513-3521
86. O'Brien S., Kantarjian H., Keating M., et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 86(9):1995;3322-3326
87. O'Brien S., Kantarjian H., Koller C., et al. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood. 93(12):1999;4149-4153
88. Scappini B., Onida F., Kantarjian H., et al. In vitro effects of STI571-containing drug combinations on growth of Ph-positive myelogenous leukemia-derived cells. Blood. 96(11):2000;99a
89. Ye X.J., Lin M.F. Homoharringtonine induces apoptosis of endothelium and down-regulates VEGF expression of K562 cells. J Zhejiang Univ Sci. 5(2):2004;230-234
90. Schwartsmann G., Fernandes M.S., Schaan M.D., et al. Decitabine (5-Aza-2′-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. Leukemia. 11(Suppl 1):1997;S28-S31
91. Wijermans P., Lubbert M., Verhoef G., et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 18(5):2000;956-962
92. Hennessy B.T., Garcia-Manero G., Kantarjian H.M., et al. DNA methylation in haematological malignancies: the role of decitabine. Expert Opin Investig Drugs. 12(12):2003;1985-1993
93. Giles F.J. New drugs in acute myeloid leukemia. Curr Oncol Rep. 4(5):2002;369-374
94. Giles F.J. Novel agents for the therapy of acute leukemia. Curr Opin Oncol. 14(1):2002;3-9
95. Zion M., Ben-Yehuda D., Avraham A., et al. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci USA. 91(22):1994;10722-10726
96. Issa J.P., Kantarjian H., Mohan A., et al. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood. 93(6):1999;2075-2080
97. Ben-Yehuda D., Krichevsky S., Rachmilewitz E.A., et al. Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia. Blood. 90(12):1997;4918-4923
98. Kantarjian H.M., O'Brien S.M., Keating M., et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia. 11(10):1997;1617-1620
99. Issa J.P., Garcia-Manero G., Giles F.J., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 103(5):2004;1635-1640
100. Lancet J.E., Karp J.E. Farnesyl transferase inhibitors in myeloid malignancies. Blood Rev. 17(3):2003;123-129
101. Beaupre D.M., Kurzrock R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol. 17(3):1999;1071-1079
102. Peters D.G., Hoover R.R., Gerlach M.J., et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 97(5):2001;1404-1412
103. Hoover R.R., Mahon F.-X., Melo J.V., et al. Overcoming STI571 resistance with the farnesyltransferase inhibitor SCH66336. Blood. 98(11):2001;617a
104. Thomas D., Cortes J., O'Brien S., et al. R115777, a farnesyl transferase inhibitor (FTI), has significant anti-leukemia activity in patients with chronic myeloid leukemia. Blood. 98(11):2001;727a
105. Cortes J., Kantarjian H., O'Brien S., et al. A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Leukemia. 11(7):1997;929-932
106. Cortes J., Kantarjian H., Talpaz M., et al. Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine. Leukemia. 11(6):1997;788-791
107. Canellos G.P. Clinical characteristics of the blast phase of chronic granulocytic leukemia. Hematol Oncol Clin N Am. 4(2):1990;359-367
108. Griffin J.D., Todd R.F. III, Ritz J., et al. Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood. 61(1):1983;85-91
109. Kantarjian H.M., Shan J., Smith T., et al. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. Cancer. 92(10):2001;2501-2507
110. Wadhwa J., Szydlo R.M., Apperley J.F., et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood. 99(7):2002;2304-2309
111. Thomas D., Kantarjian H., O'Brien S., et al. "Sudden" blastic phase (SBP) transformation in the first 2 years (YRS) of interferon-a (IFN) therapy (RX) for chronic phase (CP) chronic myelogenous leukemia (CML). Blood. 92(Suppl 1):1998;251a. Abstract 1027
112. Sawyers C.L., Hochhaus A., Feldman E., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 99(10):2002;3530-3539
113. Sacchi S., Kantarjian H.M., O'Brien S., et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 86(12):1999;2632-2641
114. Derderian P.M., Kantarjian H.M., Talpaz M., et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med. 94(1):1993;69-74
115. Branford S., Rudzki Z., Walsh S., et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 99(9):2002;3472-3475
116. Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293(5531):2001;876-880
117. Hofmann W.K., Jones L.C., Lemp N.A., et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood. 99(5):2002;1860-1862
118. Gambacorti-Passerini C., Barni R., le Coutre P., et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst. 92(20):2000;1641-1650
119. Weisberg E., Griffin J.D. Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients. Drug Resistance Updates. 4(1):2001;22-28
120. le Coutre P., Tassi E., Varella-Garcia M., et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. 95(5):2000;1758-1766
121. Mahon F.X., Deininger M.W., Schultheis B., et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 96(3):2000;1070-1079
122. La Rosee P., Johnson K., Corbin A.S., et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood. 103(1):2004;208-215
123. Inami M., Inokuchi K., Nakayama K., et al. Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia. Int J Hematol. 78(2):2003;173-175
124. Deininger M.W., McGreevey L., Willis S., et al. Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. Leukemia, in press
125. Nardi V., Azam M., Daley G.Q. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol. 11(1):2004;35-43
126. Kreil S., Muller M.C., Lahaye T., et al. Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy. Blood. 98(11):2001;435a. Abstract 1823
127. Kano Y., Akutsu M., Tsunoda S., et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood. 97(7):2001;1999-2007
128. Thiesing J.T., Ohno-Jones S., Kolibaba K.S., et al. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood. 96(9):2000;3195-3199
129. Topaly J., Zeller W.J., Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia. 15(3):2001;342-347
130. Liu W.M., Stimson L.A., Joel S.P. The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents. Br J Cancer. 86(9):2002;1472-1478
131. Kantarjian H.M., O'Brien S., Smith T.L., et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 18(3):2000;547-561
132. Giles F.J., Cortes J.E., Baker S.D., et al. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol. 19(3):2001;762-771
133. Giles F.J., Garcia-Manero G., Cortes J.E., et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol. 20(3):2002;656-664
134. Giles F.J., Faderl S., Thomas D.A., et al. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol. 21(6):2003;1050-1056
135. Grove K.L., Cheng Y.C. Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res. 56(18):1996;4187-4191
136. Giles F.J., Garcia-Manero G., Cortes J.E., et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol. 20(3):2002;656-664
137. Orsolic N., Giles F.J., Gourdeau H., et al. Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukemia: preclinical evaluation. Br J Haematol, in press
138. Karp J.E., Lancet J.E., Kaufmann S.H., et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 97(11):2001;3361-3369
139. Zangari M., Anaissie E., Stopeck A., et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res. 10(1 Pt 1):2004;88-95
140. Thomas D.A., Estey E., Giles F.J., et al. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol. 123(3):2003;436-441
141. Verstovsek S., Lunin S., Kantarjian H., et al. Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. Leuk Res. 27(7):2003;661-669
142. Giles F.J., Cooper M.A., Silverman L., et al. Phase II study of SU5416 - a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor - in patients with refractory myeloproliferative diseases. Cancer. 97(8):2003;1920-1928
143. Giles F.J., Stopeck A.T., Silverman L.R., et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 102(3):2003;795-801
144. Cortes J., Kantarjian H., Albitar M., et al. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 97(5):2003;1234-1241
145. Cortes J., Albitar M., Thomas D., et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood. 101(5):2003;1692-1697
146. Aguayo A., Kantarjian H.M., Estey E.H., et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer. 95(9):2002;1923-1930
147. Giles F.J., Kantarjian H.M., Bekele B.N., et al. Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. Br J Haematol. 119(1):2002;38-45
148. Giles F.J. The emerging role of angiogenesis inhibitors in hematologic malignancies. Oncology (Huntingt). 16(5 Suppl 4):2002;23-29
149. Verstovsek S., Estey E., Manshouri T., et al. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol. 118(1):2002;151-156
150. Verstovsek S., Kantarjian H., Manshouri T., et al. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood. 99(6):2002;2265-2267
151. Giles F.J. The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies. Oncologist. 6(Suppl 5):2001;32-39
152. Aguayo A., Estey E., Kantarjian H., et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 94(11):1999;3717-3721
153. Benjamin L.E., Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA. 94(16):1997;8761-8766
154. Clauss M. Molecular biology of the VEGF and the VEGF receptor family. Semin Thromb Hemost. 26(5):2000;561-569
155. Perez-Atayde A.R, Sallan S.E., Tedrow U., et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 150(3):1997;815-821
156. Fiedler W., Graeven U., Ergun S., et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 89(6):1997;1870-1875
157. Karp J.E., Gojo I., Gocke C., et al. Timed sequential therapy (TST) of relapsed and refractory adult acute myeloid leukemia (AML) with the anti-vascular endothelial growth factor (VEGF) monoclonal antibody Bevacizumab. Blood. 100(11):2002;198a
158. Laird A.D., Vajkoczy P., Shawver L.K., et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 60(15):2000;4152-4160
159. Thavasu P., Propper D., McDonald A., et al. The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients. Cancer Res. 59(16):1999;3980-3984
160. Panwalkar A., Verstovsek S., Giles F.J. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer. 100(4):2004;657-666
161. Yu C., Rahmani M., Almenara J., et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl + human myeloid leukemia cells. Cancer Res. 63(9):2003;2118-2126
162. Aron J.L., Parthun M.R., Marcucci G., et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase-8-mediated apoptosis and downregulation of c-FLIP protein. Blood. 20:2003;20
163. Bandyopadhyay A., Bandyopadhyay J., Chung J., et al. Inhibition of S6 kinase by rapamycin blocks maturation of Rana dybowskii oocytes. Gen Comp Endocrinol. 113(2):1999;230-239
164. Donnelly J.G., Soldin S.J. Partial characterization of a 52 kDa CsA/FK506/rapamycin binding protein. Clin Biochem. 27(5):1994;367-372
165. Herrmann A., Sommer U., Pranada A.L., et al. STAT3 is enriched in nuclear bodies. J Cell Sci. 117(Pt 2):2004;339-349
166. Inui S., Sanjo H., Maeda K., et al. Ig receptor binding protein 1 (alpha4) is associated with a rapamycin-sensitive signal transduction in lymphocytes through direct binding to the catalytic subunit of protein phosphatase 2A. Blood. 92(2):1998;539-546
167. Kardalinou E., Zhelev N., Hazzalin C.A., et al. Anisomycin and rapamycin
168. Morice W.G., Wiederrecht G., Brunn G.J., et al. Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes. J Biol Chem. 268(30):1993;22737-22745
169. Nimmanapalli R., Fuino L., Bali P., et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 63(16):2003;5126-5135
170. Nimmanapalli R., Fuino L., Stobaugh C., et al. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood. 101(8):2003;3236-3239
171. Perkins C., Kim C.N., Fang G., et al. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood. 95(3):2000;1014-1022
172. Rohde J.R., Cardenas M.E. The tor pathway regulates gene expression by linking nutrient sensing to histone acetylation. Mol Cell Biol. 23(2):2003;629-635
173. Santini V., Kantarjian H.M., Issa J.P. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med. 134(7):2001;573-586
174. Thiagalingam S., Cheng K.H., Lee H.J., et al. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci. 983:2003;84-100
175. Wang D.Z., Ray P., Boothby M. Interleukin 4-inducible phosphorylation of HMG-I(Y) is inhibited by rapamycin. J Biol Chem. 270(39):1995;22924-22932
176. Warrell R.P. Jr., He L.Z., Richon V., et al. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst. 90(21):1998;1621-1625
177. Klisovic M.I., Maghraby E.A., Parthun M.R., et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia. 17(2):2003;350-358